Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""angiogenesis"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 149112

Starter badań:

Tytuł:
Mathematical analysis to the variation of tumor cells density according to recovery of five organs: Kidney, liver, heart, spleen, and lung.
Autorzy:
Go J; Department of Electrical Engineering, Dong-A University, 37, Nakdong-daero 550beon-gil, Saha, Busan 49315, Republic of Korea. Electronic address: .
Pokaż więcej
Źródło:
Computer methods and programs in biomedicine [Comput Methods Programs Biomed] 2023 Feb; Vol. 229, pp. 107279. Date of Electronic Publication: 2022 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Spleen*
Angiogenesis Inducing Agents*
Liver ; Kidney ; Lung
Czasopismo naukowe
Szczegóły
Tytuł:
Efficacy and safety of Aflibercept for the treatment of inflammatory choroidal neovascularization: The ALINEA study.
Autorzy:
Kodjikian L; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Université Lyon 1, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Abukhashabah A; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Ophthalmology Department, King Abdulaziz University, Rabigh, Saudi Arabia.
Fardeau C; Ophthalmology Department, Reference Center for Rare Diseases, La Pitié-Salpêtriètre Hospital, Paris-Sorbonne University, Paris, France.
Tadayoni R; Université de Paris, Service d'Ophtalmologie, AP-HP, Hôpital Lariboisière, Paris, France.; Service d'Ophtalmologie, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
Brézin A; Hôpital Cochin, Service d'Ophtalmologie, Université de Paris, Paris, France.
Dumas S; Centre Nordretine, Lille, France.
Weber M; Hôpital Universitaire Centre Nantes, Nantes, France.
Bernard L; Université Lyon 1, Lyon, France.; Pôle de Santé Publique, Service de Biostatistique et Bioinformatique, Hospices Civils de Lyon, Lyon, France.; CNRS, UMR5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbane, France.
Loria O; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Decullier E; Pôle de Santé Publique, Service Recherche et Epidémiologie Cliniques, Hospices Civils de Lyon, Lyon, France.
Huot L; Université Lyon 1, Lyon, France.; Pôle de Santé Publique, Service Recherche et Epidémiologie Cliniques, Hospices Civils de Lyon, Lyon, France.
Mathis T; Hospices Civils de Lyon, Service d'Ophtalmologie, Centre Hospitalier Universitaire de la Croix-Rousse, Lyon, France.; Université Lyon 1, Lyon, France.; UMR5510 MATEIS, CNRS, INSA Lyon, Université Lyon 1, Villeurbanne, France.
Pokaż więcej
Źródło:
Acta ophthalmologica [Acta Ophthalmol] 2023 Feb; Vol. 101 (1), pp. e43-e49. Date of Electronic Publication: 2022 Jul 13.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/administration & dosage
Angiogenesis Inhibitors*/adverse effects
Choroidal Neovascularization*/drug therapy
Receptors, Vascular Endothelial Growth Factor*/administration & dosage
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/adverse effects
Humans ; Intravitreal Injections ; Prospective Studies ; Treatment Outcome ; Visual Acuity
Czasopismo naukowe
Szczegóły
Tytuł:
Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Autorzy:
Yao C; Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
Wu S; Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
Kong J; Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
Sun Y; Department of Pathology, Peking University People's Hospital, Peking University, Beijing 100044, China.
Bai Y; Department of Hepatobiliary Pancreatic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou 350001, China.
Zhu R; Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
Li Z; Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
Sun W; Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
Zheng L; The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Sciences of Ministry of Education, Health Sciences Center, Peking University, Beijing 100083, China.; Beijing Tiantan Hospital, China National Clinical Research Center of Neurological Diseases, Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100050, China.
Pokaż więcej
Źródło:
Cancer biology & medicine [Cancer Biol Med] 2023 Jan 12; Vol. 20 (1).
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Neovascularization, Pathologic*
Angiogenesis Inhibitors*/therapeutic use
Humans ; Endothelial Cells ; Tumor Microenvironment ; Vascular Endothelial Growth Factor A/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Multifunctional Electrospinning Polyhydroxyalkanoate Fibrous Scaffolds with Antibacterial and Angiogenesis Effects for Accelerating Wound Healing.
Autorzy:
Li J; Shenzhen Engineering Research Center for Medical Bioactive Materials, Center for Translational Medicine Research & Development, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Chen JN; School of Life Sciences, Center for Synthetic and Systems Biology, Tsinghua University, Beijing 100084, China.; Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing 100084, China.
Peng ZX; Shenzhen Engineering Research Center for Medical Bioactive Materials, Center for Translational Medicine Research & Development, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.
Chen NB; Research Laboratory for Biomedical Optics and Molecular Imaging, CAS Key Laboratory of Health Informatics, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Liu CB; Research Laboratory for Biomedical Optics and Molecular Imaging, CAS Key Laboratory of Health Informatics, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Zhang P; Shenzhen Engineering Research Center for Medical Bioactive Materials, Center for Translational Medicine Research & Development, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China.
Zhang X; Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing 100084, China.; Key Laboratory of Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing 100084, China.
Chen GQ; School of Life Sciences, Center for Synthetic and Systems Biology, Tsinghua University, Beijing 100084, China.; Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing 100084, China.; Key Laboratory of Industrial Biocatalysis, Ministry of Education, Department of Chemical Engineering, Tsinghua University, Beijing 100084, China.
Pokaż więcej
Źródło:
ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2023 Jan 11; Vol. 15 (1), pp. 364-377. Date of Electronic Publication: 2022 Dec 28.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inducing Agents*
Polyhydroxyalkanoates*/pharmacology
Wound Healing ; Anti-Bacterial Agents/pharmacology ; Skin ; Ciprofloxacin/pharmacology
Czasopismo naukowe
Szczegóły
Tytuł:
High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Autorzy:
Nie C; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Lv H; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Chen B; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Xu W; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Wang J; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Wang S; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Liu Y; Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.
He Y; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Zhao J; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Chen X; Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, 377327Henan Cancer Hospital, Zhengzhou, China.; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, China.; Henan Engineering Research Center of Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.; Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, Zhengzhou, China.
Pokaż więcej
Źródło:
Technology in cancer research & treatment [Technol Cancer Res Treat] 2023 Jan-Dec; Vol. 22, pp. 15330338221150561.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/pathology
Angiogenesis Inhibitors*/adverse effects
Angiogenesis Inhibitors*/therapeutic use
Tyrosine Protein Kinase Inhibitors*/adverse effects
Tyrosine Protein Kinase Inhibitors*/therapeutic use
Humans ; Hypertension/chemically induced ; Hypertension/drug therapy ; Irinotecan/adverse effects ; Neoplasm Metastasis
Czasopismo naukowe
Szczegóły
Tytuł:
Cost minimization analysis of brolucizumab in the treatment of neovascular age-related macular degeneration.
Autorzy:
Cabrera López F; Servicio de Oftalmología, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Spain.
Escobar-Barranco JJ; Servicio de Oftalmología, Hospital Dos de Maig, Barcelona, Spain.
Ventayol P; Servicio de Farmacia Hospitalaria, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
Pérez-Alcántara F; Área de Acceso al Mercado, Pharmalex Spain, Barcelona, Spain. Electronic address: .
Gómez-Baldó L; Novartis Farmacéutica SA, Barcelona, Spain.
Blanch C; Departamento de Economía de la Salud, Novartis Farmacéutica S.A., Barcelona, Spain.
Pokaż więcej
Źródło:
Archivos de la Sociedad Espanola de Oftalmologia [Arch Soc Esp Oftalmol (Engl Ed)] 2023 Mar; Vol. 98 (3), pp. 155-162. Date of Electronic Publication: 2022 Nov 09.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Macular Degeneration*/drug therapy
Humans ; Intravitreal Injections ; Costs and Cost Analysis
Czasopismo naukowe
Szczegóły
Tytuł:
Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Taiwan Premature Infant Follow-up Network Database Study.
Autorzy:
Chiang MC; Division of Neonatology, Department of Pediatrics (M.-C.C), Chang Gung Memorial Hospital, Linkou, Taiwan; Taiwan Premature Infant Follow-up Network (M.-C.C); College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan.
Chen YT; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan; Department of Ophthalmology (Y.-T.C., Y.-P.C.), New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
Kang EY; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan.
Chen KJ; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan.
Wang NK; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan.
Liu L; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan.
Chen YP; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan; Department of Ophthalmology (Y.-T.C., Y.-P.C.), New Taipei Municipal Tucheng Hospital, New Taipei City, Taiwan.
Hwang YS; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan.
Lai CC; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan; Department of Ophthalmology (C.-C.L.), Chang Gung Memorial Hospital, Keelung, Taiwan.
Wu WC; College of Medicine (M.-C.C., Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H., C.-C.L., W.-C.W.), Chang Gung University, Taoyuan, Taiwan; Department of Ophthalmology, Taiwan Premature Infant Follow-up Network (Y.-T.C., E.Y.-K, K.-J.C., N.-K.W, L.L., Y.-P.C., Y.-S.H.,, C.-C.L., W.-C.W.), Chang Gung Memorial Hospital, Linkou, Taiwan. Electronic address: .
Pokaż więcej
Źródło:
American journal of ophthalmology [Am J Ophthalmol] 2023 Mar; Vol. 247, pp. 170-180. Date of Electronic Publication: 2022 Nov 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Retinopathy of Prematurity*/drug therapy
Infant, Newborn ; Infant ; Humans ; Bevacizumab/therapeutic use ; Follow-Up Studies ; Retrospective Studies ; Taiwan ; Infant, Premature ; Gestational Age ; Intravitreal Injections
Czasopismo naukowe
Szczegóły
Tytuł:
Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience.
Autorzy:
Kaya M; Dokuz Eylül University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.
Öztürk T; Dokuz Eylül University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.
Koçak N; Dokuz Eylül University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.
Akbulut Yağcı B; Dokuz Eylül University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.
Ataş F; Dokuz Eylül University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.
Kaynak S; Dokuz Eylül University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye.
Pokaż więcej
Źródło:
Turkish journal of ophthalmology [Turk J Ophthalmol] 2023 Feb 24; Vol. 53 (1), pp. 30-36.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Diabetes Mellitus*
Diabetic Retinopathy*/complications
Diabetic Retinopathy*/diagnosis
Diabetic Retinopathy*/drug therapy
Macular Edema*/diagnosis
Macular Edema*/drug therapy
Macular Edema*/etiology
Ranibizumab*/therapeutic use
Angiogenesis Inhibitors*/therapeutic use
Humans ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration.
Autorzy:
Khachigian LM; Vascular Biology and Translational Research, Faculty of Medicine and Health, School of Medical Sciences, University of New South Wales, Sydney, NSW, 2052, Australia. .
Liew G; Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Westmead, Australia.
Teo KYC; Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore.; Duke-NUS Graduate Medical School, National University of Singapore, Singapore, Singapore.
Wong TY; Singapore National Eye Centre and Singapore Eye Research Institute, Singapore, Singapore.; Duke-NUS Graduate Medical School, National University of Singapore, Singapore, Singapore.; Tsinghua Medicine, Tsinghua University, Beijing, China.
Mitchell P; Centre for Vision Research, Westmead Institute for Medical Research, University of Sydney, Westmead, Australia.
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2023 Feb 21; Vol. 21 (1), pp. 133. Date of Electronic Publication: 2023 Feb 21.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Macular Degeneration*
Humans ; Ranibizumab/therapeutic use ; Bevacizumab/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Intravitreal Injections
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cellular Uptake of Bevacizumab in Cervical and Breast Cancer Cells Revealed by Single-Molecule Spectroscopy.
Autorzy:
Karpinska A; Department of Soft Condensed Matter, Institute of Physical Chemistry PAS, 01-224 Warsaw, Poland.
Magiera G; Department of Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland.
Kwapiszewska K; Department of Soft Condensed Matter, Institute of Physical Chemistry PAS, 01-224 Warsaw, Poland.
Hołyst R; Department of Soft Condensed Matter, Institute of Physical Chemistry PAS, 01-224 Warsaw, Poland.
Pokaż więcej
Źródło:
The journal of physical chemistry letters [J Phys Chem Lett] 2023 Feb 09; Vol. 14 (5), pp. 1272-1278. Date of Electronic Publication: 2023 Jan 31.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Breast Neoplasms*/drug therapy
Humans ; Female ; Bevacizumab ; HeLa Cells ; Single Molecule Imaging
Czasopismo naukowe
Szczegóły
Tytuł:
Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample.
Autorzy:
Hussein ZR; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq.
Omar SK; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq.
Alkazraji RAM; Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq.
Alsamarrai AN; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq.
Alrubaye HS; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq.
Al-Hussaniy HA; Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq.; Dr. Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq.; Department of Pharmacy, Bilad Alrafidain University College, Diyala, Iraq.
Pokaż więcej
Źródło:
Journal of medicine and life [J Med Life] 2023 Feb; Vol. 16 (2), pp. 235-243.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Wet Macular Degeneration*/diagnostic imaging
Wet Macular Degeneration*/drug therapy
Humans ; Treatment Outcome ; Follow-Up Studies ; Prospective Studies ; Iraq ; Vascular Endothelial Growth Factor A ; Visual Acuity ; Tomography, Optical Coherence ; Intravitreal Injections
Czasopismo naukowe
Szczegóły
Tytuł:
Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis.
Autorzy:
Xian F; Department of Oncology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China. .
Wu J
Yuan YL
Bie J
Xu GH
Pokaż więcej
Źródło:
European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2023 Feb; Vol. 27 (4), pp. 1494-1502.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/radiotherapy
Liver Neoplasms*/drug therapy
Liver Neoplasms*/radiotherapy
Humans ; Checklist
Czasopismo naukowe
Szczegóły
Tytuł:
Safety and efficacy of an artificial intelligence-enabled decision tool for treatment decisions in neovascular age-related macular degeneration and an exploration of clinical pathway integration and implementation: protocol for a multi-methods validation study.
Autorzy:
Hogg HDJ; Population Health Sciences Institute, University of Newcastle upon Tyne, Newcastle upon Tyne, UK .; Newcastle Eye Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Brittain K; Population Health Sciences Institute, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.
Teare D; Population Health Sciences Institute, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.
Talks J; Newcastle Eye Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
Balaskas K; Institute of Ophthalmology, University College London, London, UK.; Moorfields Eye Hospital City Road Campus, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Keane P; Institute of Ophthalmology, University College London, London, UK.; Moorfields Eye Hospital City Road Campus, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Maniatopoulos G; Population Health Sciences Institute, University of Newcastle upon Tyne, Newcastle upon Tyne, UK.; Faculty of Business and Law, Northumbria University, Newcastle upon Tyne, UK.
Pokaż więcej
Źródło:
BMJ open [BMJ Open] 2023 Feb 01; Vol. 13 (2), pp. e069443. Date of Electronic Publication: 2023 Feb 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Macular Degeneration*/drug therapy
Humans ; Critical Pathways ; State Medicine ; Artificial Intelligence ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [ C] SHC014748M in healthy Chinese subjects following oral administration.
Autorzy:
Guo F; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; Department of Radiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; Department of Medical Imaging Diagnosis, School of Medical Imaging, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Liu B; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Li X; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Wang H; Department of Pharmacy, The Affiliated Lianyungang Hospital of Xuzhou Medical University/The First People's Hospital of Lianyungang, Lianyungang, 222000, People's Republic of China.
Zhu X; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Su Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Public Foundation, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
He C; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Zhu M; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Ding J; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Public Foundation, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Xu Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Zhao X; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Wang Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Shan R; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Zhu J; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Xie J; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Ge Q; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Fan L; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Ding Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Xie Y; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Zhang C; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Li H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Wang H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China. .
Zhou H; National Institute of Clinical Drug Trials, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China. .; School of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China. .; School of Public Foundation, Bengbu Medical College, Bengbu, Anhui, People's Republic of China. .
Pokaż więcej
Źródło:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Feb; Vol. 91 (2), pp. 143-156. Date of Electronic Publication: 2022 Dec 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors*/pharmacokinetics
Glucuronides*/analysis
Protein Kinase Inhibitors*/pharmacokinetics
Humans ; Male ; Administration, Oral ; Carbon Radioisotopes/analysis ; East Asian People ; Feces/chemistry
Czasopismo naukowe
Szczegóły
Tytuł:
The value of handholding during intravitreal injections.
Autorzy:
Shaughnessy D; UCD School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
Powell S; UCD School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.
O'Toole L; Bon Secours Hospital, Dublin, Ireland. .
Pokaż więcej
Źródło:
Irish journal of medical science [Ir J Med Sci] 2023 Feb; Vol. 192 (1), pp. 441-445. Date of Electronic Publication: 2022 Mar 24.
Typ publikacji:
Journal Article
MeSH Terms:
Anxiety*/prevention & control
Angiogenesis Inhibitors*
Humans ; Intravitreal Injections ; Surveys and Questionnaires
Czasopismo naukowe
Szczegóły
Tytuł:
Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis.
Autorzy:
Tsai CY; Taipei City Hospital, Taipei City, Taiwan.; Institute of Public Health, National Yang Ming Chiao Tung University, Taipei City, Taiwan.; Department of Business Administration, Fu Jen Catholic University, New Taipei City, Taiwan.
Wu CL; Municipal Wan Fang Hospital, Taipei City, Taiwan.
Cheng CK; Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan.
Shen YD; Taipei Medical University-Shung Ho Hospital, New Taipei City, Taiwan.; Kang-Ning General Hospital, Taipei City, Taiwan.
Wu WC; Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan.; Park One International Hospital, Kaohsiung City, Taiwan.
Wu PC; Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan.
Tsai A; Clinical Development and Medical Affairs, Novartis Taiwan, Taipei City, Taiwan.
Chen JT; Tri-Service General Hospital, Chenggong Road, Taipei City 114, Taiwan. .; National Defense Medical Center, Taipei City, Taiwan. .
Pokaż więcej
Źródło:
BMC ophthalmology [BMC Ophthalmol] 2023 Jan 27; Vol. 23 (1), pp. 39. Date of Electronic Publication: 2023 Jan 27.
Typ publikacji:
Clinical Study; Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Ranibizumab*/therapeutic use
Adult ; Humans ; Intravitreal Injections ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Szczegóły
Tytuł:
Aflibercept more effectively weans patients with neovascular age-related macular degeneration off therapy compared with bevacizumab.
Autorzy:
Cao X; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sanchez JC; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Patel TP; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yang Z; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Guo C; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Malik D; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sopeyin A; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Montaner S; Department of Oncology and Diagnostic Sciences, School of Dentistry, Department of Pathology, School of Medicine, University of Maryland School of Dentistry, Baltimore, Maryland, USA; Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
Sodhi A; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Pokaż więcej
Źródło:
The Journal of clinical investigation [J Clin Invest] 2023 Jan 17; Vol. 133 (2). Date of Electronic Publication: 2023 Jan 17.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Macular Degeneration*/drug therapy
Humans ; Bevacizumab/therapeutic use ; Ranibizumab/adverse effects ; Retrospective Studies ; Recombinant Fusion Proteins/therapeutic use ; Treatment Outcome ; Follow-Up Studies
Czasopismo naukowe
Szczegóły
Tytuł:
Evaluation of Multiple Machine Learning Models for Predicting Number of Anti-VEGF Injections in the Comparison of AMD Treatment Trials (CATT).
Autorzy:
Chandra RS; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ying GS; Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pokaż więcej
Źródło:
Translational vision science & technology [Transl Vis Sci Technol] 2023 Jan 03; Vol. 12 (1), pp. 18.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Macular Degeneration*/drug therapy
Humans ; Child, Preschool ; Intravitreal Injections ; Ranibizumab/therapeutic use ; Machine Learning
Czasopismo naukowe
Szczegóły
Tytuł:
Intra-ocular pressure changes after intravitreal injection of bevacizumab.
Autorzy:
Iqbal U; Department of Ophthalmology, DHQ Teaching Hospital, Gujranwala Medical College, Gujranwala, Pakistan.
Malik IQ; Ophthalmology Department, Gujranwala Medical College/ Teaching Hospital, Gujranwala, Pakistan.
Jabran A; Department of Ophthalmology, DHQ Teaching Hospital, Gujranwala Medical College, Gujranwala, Pakistan.
Pokaż więcej
Źródło:
JPMA. The Journal of the Pakistan Medical Association [J Pak Med Assoc] 2023 Jan; Vol. 73 (1), pp. 64-68.
Typ publikacji:
Journal Article
MeSH Terms:
Intraocular Pressure*
Angiogenesis Inhibitors*/therapeutic use
Humans ; Male ; Female ; Middle Aged ; Bevacizumab/adverse effects ; Intravitreal Injections ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Szczegóły
Tytuł:
Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature.
Autorzy:
Gan G; Department of Ophthalmology, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France.
Michel M; Department of Nephrology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Metz, France.
Max A; Cypath Metz, Cytopathology Laboratory, Metz, France.
Sujet-Perone N; Department of Nephrology, Robert Debré Hospital, Reims University Hospital Center, Reims, France.
Zevering Y; Department of Ophthalmology, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France.
Vermion JC; Department of Ophthalmology, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France.
Zaidi M; Department of Ophthalmology, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France.
Savenkoff B; Department of Nephrology, Mercy Hospital, Metz-Thionville Regional Hospital Center, Metz, France.
Perone JM; Department of Ophthalmology, Metz-Thionville Regional Hospital Center, Mercy Hospital, Metz, France.
Pokaż więcej
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2023 Jan; Vol. 89 (1), pp. 401-409. Date of Electronic Publication: 2022 Nov 12.
Typ publikacji:
Review; Case Reports
MeSH Terms:
Angiogenesis Inhibitors*/adverse effects
Glomerulonephritis, Membranoproliferative*/chemically induced
Glomerulonephritis, Membranoproliferative*/drug therapy
Humans ; Middle Aged ; Bevacizumab ; Vascular Endothelial Growth Factor A ; Growth Inhibitors ; Intravitreal Injections ; Ranibizumab/therapeutic use ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins
Recenzja
Szczegóły
Wyświetlanie 1-20 z 149112

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz